CU24263B1 - Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer - Google Patents

Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer

Info

Publication number
CU24263B1
CU24263B1 CUP2013000135A CU20130135A CU24263B1 CU 24263 B1 CU24263 B1 CU 24263B1 CU P2013000135 A CUP2013000135 A CU P2013000135A CU 20130135 A CU20130135 A CU 20130135A CU 24263 B1 CU24263 B1 CU 24263B1
Authority
CU
Cuba
Prior art keywords
cancer
useful
treatment
akt
inhibitors
Prior art date
Application number
CUP2013000135A
Other languages
English (en)
Other versions
CU20130135A7 (es
Inventor
Lars Bärfacker
Ulf Bömer
Hans Briem
Andrea Hägebarth
Stuart Ince
Roland Neuhaus
Oliver Politz
Hartmut Rehwinkel
William Johnston Scott
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of CU20130135A7 publication Critical patent/CU20130135A7/es
Publication of CU24263B1 publication Critical patent/CU24263B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

<p>La invención se refiere a las imidazopiridazinas de fórmula (I)</p> <p>Espacio para Fórmula I</p> <p>que actúan en calidad de inhibidores de quinasa AKT y son útiles para el tratamiento del cáncer, y a un proceso para su preparación.</p>
CUP2013000135A 2011-04-07 2012-04-05 Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer CU24263B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472732P 2011-04-07 2011-04-07
PCT/EP2012/056300 WO2012136776A1 (en) 2011-04-07 2012-04-05 Imidazopyridazines as akt kinase inhibitors

Publications (2)

Publication Number Publication Date
CU20130135A7 CU20130135A7 (es) 2014-02-28
CU24263B1 true CU24263B1 (es) 2017-07-04

Family

ID=45953129

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2013000135A CU24263B1 (es) 2011-04-07 2012-04-05 Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer

Country Status (43)

Country Link
US (2) US9206185B2 (es)
EP (1) EP2694510B1 (es)
JP (1) JP5906303B2 (es)
KR (1) KR20140022057A (es)
CN (1) CN103596957B (es)
AP (1) AP3597A (es)
AR (1) AR087148A1 (es)
AU (1) AU2012238589B2 (es)
BR (1) BR112013025777A2 (es)
CA (1) CA2832374A1 (es)
CL (1) CL2013002878A1 (es)
CO (1) CO6862145A2 (es)
CR (1) CR20130515A (es)
CU (1) CU24263B1 (es)
CY (1) CY1117163T1 (es)
DK (1) DK2694510T3 (es)
DO (1) DOP2013000226A (es)
EA (1) EA024890B1 (es)
EC (1) ECSP13013008A (es)
ES (1) ES2558780T3 (es)
GT (1) GT201300238A (es)
HR (1) HRP20160011T1 (es)
HU (1) HUE026323T2 (es)
IL (1) IL228567A0 (es)
JO (1) JO3068B1 (es)
MA (1) MA35016B1 (es)
ME (1) ME02316B (es)
MX (1) MX336865B (es)
NI (1) NI201300105A (es)
PE (1) PE20141380A1 (es)
PH (1) PH12013502073A1 (es)
PL (1) PL2694510T3 (es)
PT (1) PT2694510E (es)
RS (1) RS54480B1 (es)
SG (1) SG193631A1 (es)
SI (1) SI2694510T1 (es)
SM (1) SMT201600001B (es)
TN (1) TN2013000400A1 (es)
TW (1) TWI535719B (es)
UA (1) UA111739C2 (es)
UY (1) UY34006A (es)
WO (1) WO2012136776A1 (es)
ZA (1) ZA201307223B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
DK2303021T3 (en) 2008-06-16 2019-04-08 Univ Tennessee Res Found RELATIONSHIPS FOR TREATING CANCER
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
KR101939704B1 (ko) 2010-03-01 2019-01-17 지티엑스, 인코포레이티드 암 치료용 화합물
EA024890B1 (ru) * 2011-04-07 2016-10-31 Байер Интеллектчуал Проперти Гмбх Имидазопиридазины в качестве ингибиторов akt киназы
WO2013104610A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
CN104066736B (zh) * 2012-01-10 2017-03-08 拜耳知识产权有限责任公司 作为akt激酶抑制剂的取代的吡唑并嘧啶
MA38121A1 (fr) * 2012-11-30 2016-10-31 Glaxosmithkline Llc Nouvelle composition pharmaceutique
CN105163584B (zh) * 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
WO2014158467A1 (en) * 2013-03-12 2014-10-02 Glaxosmithkline Llc Combination
JP2016517434A (ja) * 2013-03-14 2016-06-16 エピザイム，インコーポレイティド 癌を処置するための併用療法
US10214545B2 (en) * 2014-01-09 2019-02-26 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
CN110225912B (zh) * 2016-11-28 2022-10-21 百时美施贵宝公司 Gsk-3抑制剂
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649629B2 (en) 1999-12-23 2003-11-18 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
EP1268478B1 (en) 2000-03-31 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
AU2001252609A1 (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd. Imidazopyridine derivatives
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
WO2004096131A2 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
WO2005014598A1 (en) 2003-07-30 2005-02-17 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazopyrimidines for the prevention and treatment of cancer
EP1737843B1 (en) 2004-04-09 2011-02-23 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2005290081B2 (en) 2004-08-23 2010-12-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
JP2008510741A (ja) 2004-08-24 2008-04-10 ビーエーエスエフ ソシエタス・ヨーロピア イオン液体を製造するための出発化合物としてのイミダゾリウム−メチルスルファイト
WO2006065601A2 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Inhibitors of akt activity
RU2007147382A (ru) 2005-05-20 2009-06-27 Эррэй Биофарма Инк. (Us) Соединения, являющиеся ингибиторами raf, и способы их применения
AU2006258124B8 (en) 2005-06-10 2010-01-07 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
BRPI0811065A2 (pt) * 2007-06-08 2014-12-02 Abbott Lab Indazóis 5-heteroaril substituídos como inibidores de quinase
UY31293A1 (es) 2007-08-14 2009-03-31 Pirimidinas biciclicas fusionadas
DE602008005894D1 (de) * 2007-08-14 2011-05-12 Bayer Schering Pharma Ag Kondensierte imidazole zur krebsbehandlung
WO2009086130A1 (en) 2007-12-21 2009-07-09 Wyeth Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
AU2009255358A1 (en) 2008-06-03 2009-12-10 Msd K.K. Inhibitors of Akt activity
CA2726358A1 (en) 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
WO2010088177A1 (en) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
KR20110114663A (ko) * 2009-02-13 2011-10-19 바이엘 파마 악티엔게젤샤프트 융합된 피리미딘
WO2010104933A1 (en) 2009-03-11 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010114780A1 (en) * 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
EP2473495A1 (en) 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
JP5830094B2 (ja) * 2010-07-12 2015-12-09 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾ［１，２−ａ］ピリミジンおよび−ピリジン
ES2539257T3 (es) * 2010-07-28 2015-06-29 Bayer Intellectual Property Gmbh Imidazo[1,2-b]piridazinas sustituidas
EA024890B1 (ru) * 2011-04-07 2016-10-31 Байер Интеллектчуал Проперти Гмбх Имидазопиридазины в качестве ингибиторов akt киназы

Also Published As

Publication number Publication date
WO2012136776A1 (en) 2012-10-11
UA111739C2 (uk) 2016-06-10
HUE026323T2 (en) 2016-05-30
CN103596957A (zh) 2014-02-19
TN2013000400A1 (en) 2015-03-30
TWI535719B (zh) 2016-06-01
EA201301130A1 (ru) 2014-07-30
US9604989B2 (en) 2017-03-28
NI201300105A (es) 2014-07-14
US9206185B2 (en) 2015-12-08
ES2558780T3 (es) 2016-02-08
IL228567A0 (en) 2013-12-31
EP2694510A1 (en) 2014-02-12
AU2012238589B2 (en) 2017-02-16
CL2013002878A1 (es) 2014-05-02
MX2013011699A (es) 2014-01-31
CR20130515A (es) 2013-12-04
RS54480B1 (sr) 2016-06-30
AR087148A1 (es) 2014-02-26
ZA201307223B (en) 2014-12-23
SG193631A1 (en) 2013-11-29
AP3597A (en) 2016-02-19
US20150368250A1 (en) 2015-12-24
CA2832374A1 (en) 2012-10-11
KR20140022057A (ko) 2014-02-21
PH12013502073A1 (en) 2014-01-13
SMT201600001B (it) 2016-02-25
ME02316B (me) 2016-06-20
PT2694510E (pt) 2016-02-08
HRP20160011T1 (hr) 2016-02-12
AP2013007215A0 (en) 2013-10-31
CN103596957B (zh) 2016-12-07
JO3068B1 (ar) 2017-03-15
CY1117163T1 (el) 2017-04-05
ECSP13013008A (es) 2013-12-31
DK2694510T3 (en) 2016-01-18
US20140113901A1 (en) 2014-04-24
MA35016B1 (fr) 2014-04-03
AU2012238589A1 (en) 2013-11-07
BR112013025777A2 (pt) 2016-12-20
JP2014510127A (ja) 2014-04-24
JP5906303B2 (ja) 2016-04-20
MX336865B (es) 2016-02-04
TW201245204A (en) 2012-11-16
CU20130135A7 (es) 2014-02-28
CO6862145A2 (es) 2014-02-10
SI2694510T1 (sl) 2016-02-29
UY34006A (es) 2012-10-31
DOP2013000226A (es) 2013-11-15
EA024890B1 (ru) 2016-10-31
PE20141380A1 (es) 2014-10-18
GT201300238A (es) 2015-04-06
NZ616270A (en) 2015-09-25
EP2694510B1 (en) 2015-10-14
PL2694510T3 (pl) 2016-03-31

Similar Documents

Publication Publication Date Title
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
PH12017502141A1 (en) Compounds and their methods of use
UY34960A (es) Dihidropiridona p1 como inhibidores del factor xia
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
SV2017005487A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
UY35975A (es) Macrociclos con grupos p2? heterocíclicos como inhibidores del factor xia
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
MX2017003695A (es) Pirimidinonas como inhibidores del factor xia.
UY34959A (es) Dihidropiridona p1 como inhibidores del factor xia
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
MX378194B (es) Compuestos organicos.
TR201816379T4 (tr) DNA-PK inhibitörleri.
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
NI201300105A (es) Imidazopiridazinas como inhibidores de quinasa akt
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
NZ711192A (en) Process for making benzoxazepin compounds
MX349548B (es) Compuestos de tienopirimidina.
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2